DIAMEDICA
DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circu... lation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.
DIAMEDICA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.diamedica.com
Total Employee:
1+
Status:
Active
Contact:
(763)270-0603
Total Funding:
87.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache
Current Employees Featured
Kirsten Gruis Chief Medical Officer @ DiaMedica
Chief Medical Officer
2022-01-01
Dominic Cundari Chief Commercial Officer @ DiaMedica
Chief Commercial Officer
2022-02-01
Scott Kellen Chief Financial Officer @ DiaMedica
Chief Financial Officer
2018-04-01
Wayne Lautt Co-Founder @ DiaMedica
Co-Founder
Rick Pauls President & CEO @ DiaMedica
President & CEO
2010-02-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-06-30 | Sanomune | Sanomune acquired by DiaMedica | N/A |
Investors List
SK Group
SK Group investment in Post-IPO Equity - DiaMedica
Fosun Pharma
Fosun Pharma investment in Post-IPO Equity - DiaMedica
Hermed Capital
Hermed Capital investment in Post-IPO Equity - DiaMedica
Genesys Venture
Genesys Venture investment in Pre Seed Round - DiaMedica
Key Employee Changes
Official Site Inspections
http://www.diamedica.com Semrush global rank: 2.72 M Semrush visits lastest month: 6.03 K
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "DiaMedica"
Investor Relations :: DiaMedica Therapeutics, Inc. (DMAC)
Feb 24, 2025 DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically …See details»
DiaMedica - Crunchbase Company Profile & Funding
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments …See details»
DiaMedica Therapeutics Inc. | LinkedIn
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are ...See details»
DiaMedica Org Chart + Executive Team - The Official …
Organizational Chart of DiaMedica. DiaMedica Org Chart www.diamedica.com. has 17 executives +1 763 270 0603; Add an executive. DiaMedica (DMAC) News . Anything missing? We search for you. Print or download . CEO & Director. …See details»
DiaMedica Therapeutics - Craft
Oct 29, 2024 DiaMedica Therapeutics is a biopharmaceutical company which engages in the development of treatments for neurological and kidney diseases. The Company's lead product …See details»
About DiaMedica :: DiaMedica Therapeutics, Inc. (DMAC)
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company committed to changing the treatment paradigm for acute ischemic stroke (AIS) and preeclampsia (PE). Our initial product candidate, DM199, mimics the …See details»
Leadership Team :: DiaMedica Therapeutics, Inc. (DMAC)
Before joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from 2002 until 2010. Mr. Pauls was an analyst for Centara Corporation, an early …See details»
Diamedica Inc. Company Profile | Winnipeg, MB, Canada
Diamedica Inc. Website. Get a D&B Hoovers Free Trial. Overview Company Description:? Key Principal: Dia Medica See more contacts Industry: Offices of Physicians , Ambulatory Health …See details»
Diamedica - Devex
Diamedica is the market leader of anaesthetic equipment for challenging environments. Designed for simplicity, economy and reliability, their range of anaesthetic machines function effectively …See details»
DiaMedica Therapeutics - LifeScienceHistory.com
DiaMedica Therapeutics www.diamedica.com. 301 Carlson Parkway, Suite 210. Minnetonka, MN 55305. Company Info Phone (763) 496-5454 Year Established 2000 Ticker DMAC ExchangeSee details»
DiaMedica - Funding, Financials, Valuation & Investors - Crunchbase
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.See details»
Diamedica | Safe anaesthesia and respiratory solutions
"Diamedica's Vital Role: Emergency Medical Equipment Supply in Ukraine's Humanitarian Aid Efforts" Read Post Safe anaesthesia solutions. Our products are robust, easy to operate and …See details»
DiaMedica Therapeutics Provides a Business Update and …
May 9, 2024 The activation of study sites in Canada is expected to begin in the fourth quarter of 2024. The Australian Stroke Trials Network has completed its endorsement of DiaMedica’s …See details»
DiaMedica - Contacts, Employees, Board Members, Advisors
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke.See details»
dmtp20210427_10ka.htm - SEC.gov
Apr 27, 2021 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) _____ British Columbia ... Middle East and Africa and the Commonwealth of …See details»
DiaMedica Therapeutics: Stroke Developer With Low Cash Reserve
5 days ago DiaMedica maintains a low liquidity profile with modest cash burn and a short cash runway During the earnings call, CFO Kellen reported that DiaMedica's cash and investments …See details»
Board of Directors :: DiaMedica Therapeutics, Inc. (DMAC)
Before joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures, an early-stage life sciences venture capital fund, from 2002 until 2010. Mr. ... a …See details»
DiaMedica Therapeutics Provides a Business Update and
Mar 17, 2025 DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic …See details»
Diamedica
Diamedica is Australia’s leading supplier of diabetes monitoring technology. We partner with the best global brands and leading manufacturers to bring you high quality technology. View …See details»
DiaMedica Therapeutics Provides a Business Update and …
Mar 17, 2025 MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments …See details»